The invention relates to a method for the treatment of a disease susceptible to anti-EGFR treatment, comprising the step of administering, to a human being in nee thereof, a combination of an anti-EGFR agent and an anti-neutrophil-chemoattracta agent, wherein said anti-neutrophil-chemoattractant age
The invention relates to a method for the treatment of a disease susceptible to anti-EGFR treatment, comprising the step of administering, to a human being in nee thereof, a combination of an anti-EGFR agent and an anti-neutrophil-chemoattracta agent, wherein said anti-neutrophil-chemoattractant agent is administered in a dosage regimen that is sufficient to reduce one or more undesired dermatological side-effects the anti-EGFR agent. In one embodiment, the anti-EGFR agent is an anti-EGF antibody and the anti-neutrophil-chemoattractant agent is an anti-IL-8 antibody.
대표청구항▼
1. A method for treating or rash associated with anti-EGFR treatment comprising: (a) identifying a subject who is undergoing anti-EGFR treatment and has a rash, wherein said anti-EGFR treatment comprises administering a quinazoline derivative or an antibody capable of binding to EGFR; and(b) adminis
1. A method for treating or rash associated with anti-EGFR treatment comprising: (a) identifying a subject who is undergoing anti-EGFR treatment and has a rash, wherein said anti-EGFR treatment comprises administering a quinazoline derivative or an antibody capable of binding to EGFR; and(b) administering, to the subject, an anti-IL8 antibody in an amount sufficient to treat or reduce the rash, wherein the antibody blocks the binding of IL8 to its receptor. 2. The method of claim 1, wherein said anti-EGFR treatment is for treating cancer. 3. The method of claim 2, wherein said cancer is selected from the group consisting of: breast cancer, bladder cancer, uterine/cervical cancer, esophageal cancer, pancreatic cancer, colorectal cancer, kidney cancer, ovarian cancer, prostate cancer, head and neck cancer, non-small cell lung cancer and stomach cancer. 4. The method of claim 2, wherein said cancer is head and neck cancer or non small-cell lung cancer. 5. The method of claim 1, wherein said anti-EGFR treatment comprises administering an antibody capable of binding to EGFR. 6. The method of claim 5, wherein said antibody binds to human EGFR with an equilibrium dissociation constant (KD) of at most 10−8 M. 7. The method of claim 5, wherein the antibody is able to compete with an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs: 3 and 4, respectively. 8. The method of claim 5, wherein the anti-EGFR antibody is administered, at least once per 14 days, at a dose of at least 0.1 mg/kg. 9. The method of claim 8, wherein the anti-EGFR antibody is administered at least once per week. 10. The method of claim 8, wherein the anti-EGFR antibody is administered for a total duration of at least one month. 11. The method of claim 1, wherein said anti-EGFR treatment comprises administering a quinazoline derivative capable of binding to EGFR. 12. The method of claim 1, wherein the anti-IL8 antibody binds to human IL8 with an equilibrium dissociation constant (KD) of at most 10−10 M. 13. The method of claim 1, wherein the anti-IL8 antibody is able to compete with an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs: 10 and 11, respectively. 14. The method of claim 1, wherein the anti-IL8 antibody is administered, at least once per 14 days, at a dose of at least 1.5 mg/kg. 15. The method of claim 14, wherein the anti-IL8 antibody is administered at least once per week. 16. The method of claim 14, wherein the anti-IL8 antibody is administered for a total duration of at least one month. 17. The method of claim 1, wherein said rash is reduced by at least 10%. 18. The method of claim 1, wherein an anti-EGFR treatment and the anti-IL8 antibody are administered on the same day. 19. The method of claim 1, wherein the anti-IL8 antibody is administered at least one day before an anti-EGFR treatment. 20. The method of claim 1, wherein the anti-EGFR treatment is administered parenterally. 21. The method of claim 1, wherein the anti-IL8 antibody is administered parenterally. 22. The method of claim 1, wherein said subject is a human being susceptible to developing rash when subjected to anti-EGFR treatment. 23. The method of claim 1, comprising administration of one or more further therapies selected from chemotherapeutic agents, immunosuppressive agents, anti-inflammatory agents, anti-psoriasis agents, radiation therapy, hyperthermia, transplantation, surgery, sunlight therapy, and phototherapy. 24. The method of claim 1, comprising administration of one or more further therapies selected from the group consisting of nitrogen mustards, aziridines, alkyl sulfonates, nitrosoureas, platinum complexes, non-classical alkylating agents, folate analogs, purine analogs, adenosine analogs, pyrimidine analogs, substituted ureas, antitumor antibiotics, epipodophyllotoxins, microtubule agents, camptothecin analogs, enzymes, cytokines, monoclonal antibodies, recombinant toxins and immunotoxins, cancer gene therapies, cancer vaccines, radiation therapy, hyperthermia, transplantation, and surgery. 25. The method of claim 1, comprising administration of one or more further therapies selected from the group consisting of immunosuppressive anti-bodies against MHC, CD2, CD3, CD4, CD7, CD28, B7, CD40, CD45, IFN-gamma, TNF-alpha, IL-4, IL-5, IL-6R, IL-7, IL-10, CD11a, CD20, and CD58 or antibodies against their ligands, soluble IL-15R, and IL-10. 26. The method of claim 1, comprising administration of one or more further therapies selected from the group consisting of cyclosporine, azathioprine, mycophenolic acid, mycophenolate mofetil, corticosteroids, methotrexate, gold salts, sulfasalazine, antimalarials, brequinar, leflunomide, mizoribine, 15-deoxyspergualine, 6-mercaptopurine, cyclophosphamide, rapamycin, tacrolimus, OKT3, anti-thymocyte globulin, transplantation, and surgery. 27. The method of claim 1, comprising administration of one or more further therapies selected from the group consisting of aspirin, salicylates, steroidal drugs, nonsteroidal anti-inflammatory drugs, Cox-2inhibitors, and disease modifying antirheumatic drugs. 28. The method of claim 1, comprising administration of one or more further therapies selected from the group consisting of coal tar, A vitamin, anthralin, calcipotrien, tarazotene, retinoids, etanercept, alefacept, efaluzimab, 6-thioguanine, hydroxyurea, sunlight therapy, and phototherapy. 29. The method of claim 5, wherein the anti-EGFR antibody is a human antibody. 30. The method of claim 5, wherein said anti-EGFR antibody comprises heavy and light chain variable regions having the amino acid sequence set forth in SEQ ID NOs: 3 and 4, respectively. 31. The method of claim 5, wherein the anti-EGFR antibody comprises a) heavy chain CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:5, 6, and 1, respectively; and (b) light chain CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:7, 8, and 9, respectively. 32. The method of claim 1, wherein said antibody comprises heavy and light chain variable regions having the amino acid sequence set forth in SEQ ID NOs: 10 and 11, respectively. 33. The method of claim 1, wherein said anti-IL8 antibody comprises a) a heavy chain variable region comprising CDR1, CDR2, and CDR3sequences comprising the amino acid sequences set forth in SEQ ID NOs:12, 13, and 2, respectively; and (b) a light chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:14, 15, and 16, respectively. 34. The method of claim 12, wherein said antibody binds to human IL8 with an equilibrium dissociation constant (KD) of at most 10−10 M.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (46)
Vishnupad, Mohan, Anhydrous creams, lotions and gels.
Stella Valentino J. (Lawrence KS) Rajewski Roger (Lawrence KS), Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof.
Philippe Michel (Antony FRX), Dipeptidic amides derived from glycyl-serine as surfactants or hydrating agents and cosmetic, pharmaceutical or alimenta.
Pusztai Arpad Janos,GBX ; Bardocz Zsuzsanna Magdolna,GBX ; Palmer Richard Michael John,GBX ; Fish Neil William,GBX ; Koteles Gyorgy J.,HUX, Lectin compositions and uses thereof.
DeMichele Stephen J. ; Lee Theresa W. ; Tso Patrick, Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides.
DeMichele Stephen J. ; Lee Theresa W. ; Tso Patrick, Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champagne IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champagne IL) Desai Neil P. (Los Angeles CA), Methods for in vivo delivery of nutriceuticals and compositions useful therefor.
Sankarasubbier, Narayanan; Murthy, Katravulapalli V.V.S.B.S.; Reddy, Kongara Madhusudan; Nandhikonda, Premchendar, Process for preparation of 2-Methyl-1,4-naphthoquinone.
Hahnlein Wolfgang,DEX ; Hansen Morten Mohr,DKX ; Olesen Jes Elenius,DKX ; Tobiasen Anne Grethe,DKX, Stable emulsions and dry powders of mixtures of fat-soluble vitamins, their preparation and use.
Schneider Joachim U. (Weisenheim DEX) Schumacher Horst (Bobenheim DEX) Bewert Wolfgang (Frankenthal DEX) Gaus Guenter (Biblis DEX) Rheude Udo (Otterstadt DEX), Stable vitamin and/or carotenoid products in powder form, and the preparation thereof.
Posner Barry I. (360 Wood Ave. Westmount ; Quebec CAX H3Z 1Z2) Fantus I. George (4745 Meridian Montreal ; Quebec CAX H3W 2C2), Use of pervanadate as an inhibitor of phosphotyrosine phosphatase.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.